Reach Us +1-218-451-2974


Breaking The Code Of Amyloid-? Oligomers | 12471
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per Google Scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Breaking the code of amyloid-? oligomers

International Conference on Psychology, Autism and Alzheimers Disease

Sylvain E. Lesne

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.S1.002

For a century, the cardinal features of Alzheimer?s disease (AD), amyloid plaques and neurofibrillary tangles, were thought to underlie this chronic neurological disorder. However, based on the evidence accumulated over the past ten to fifteen years, the toxicity of these lesions has been questioned. Instead the emerging soluble aggregation-intermediate forms of amyloid-beta (A?) and tau proteins, which compose plaques and tangles, are now believed to underlie the synaptic and neuronal losses observed in AD. Studies focusing on oligomeric A? assemblies have paved the way for other amyloid proteins including tau, alpha-synuclein and the prion protein PrP in the field of neurodegenerative disorders. This paradigm shift also contributed to complicating even more the putative sequence of biological events responsible for these diseases. The modern view of the amyloid hypothesis suggests the involvement of a multitude of endogenous bioactive A? molecules that includes A? dimers, trimers, A?*56, annular protofibrils and amyloid plaques, as opposed to a single culprit (i.e. plaques). This increased complexity of the problem coupled with a lack of adequate experimental descriptions of the A? oligomers used renders interpretation and comparison of the observed phenomena between different research groups arduous and impedes on our progress to better understand the role of A? oligomers in AD. Here, I will try to answer key questions related to A? oligomers using our recent data on endogenous A? oligomers and argue why we should care about A? oligomers and how asking simple questions might generate impactful answers.
Sylvain Lesne attended college at the Universite de Caen, Basse-Normandie where he graduated with a master?s degree in Biochemistry (major in Neuroscience) and a Ph.D. in Molecular and Cellular Biology (major in Neuroscience). He joined Karen H. Ashe?s laboratory at the University of Minnesota in November 2002 as a postdoctoral research associate and moved on to becoming a research associate 2 years later. In December 2009, he joined the N. Bud Grossman Center for Memory Research and Care as an Institute for Translational Neuroscience Scholar and tenure-track Assistant Professor (Department of Neuroscience).